891 related articles for article (PubMed ID: 29892070)
1. An inhibitor of oxidative phosphorylation exploits cancer vulnerability.
Molina JR; Sun Y; Protopopova M; Gera S; Bandi M; Bristow C; McAfoos T; Morlacchi P; Ackroyd J; Agip AA; Al-Atrash G; Asara J; Bardenhagen J; Carrillo CC; Carroll C; Chang E; Ciurea S; Cross JB; Czako B; Deem A; Daver N; de Groot JF; Dong JW; Feng N; Gao G; Gay J; Do MG; Greer J; Giuliani V; Han J; Han L; Henry VK; Hirst J; Huang S; Jiang Y; Kang Z; Khor T; Konoplev S; Lin YH; Liu G; Lodi A; Lofton T; Ma H; Mahendra M; Matre P; Mullinax R; Peoples M; Petrocchi A; Rodriguez-Canale J; Serreli R; Shi T; Smith M; Tabe Y; Theroff J; Tiziani S; Xu Q; Zhang Q; Muller F; DePinho RA; Toniatti C; Draetta GF; Heffernan TP; Konopleva M; Jones P; Di Francesco ME; Marszalek JR
Nat Med; 2018 Jul; 24(7):1036-1046. PubMed ID: 29892070
[TBL] [Abstract][Full Text] [Related]
2. OXPHOS-targeting drugs in oncology: new perspectives.
Kalyanaraman B; Cheng G; Hardy M; You M
Expert Opin Ther Targets; 2023; 27(10):939-952. PubMed ID: 37736880
[TBL] [Abstract][Full Text] [Related]
3. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials.
Yap TA; Daver N; Mahendra M; Zhang J; Kamiya-Matsuoka C; Meric-Bernstam F; Kantarjian HM; Ravandi F; Collins ME; Francesco MED; Dumbrava EE; Fu S; Gao S; Gay JP; Gera S; Han J; Hong DS; Jabbour EJ; Ju Z; Karp DD; Lodi A; Molina JR; Baran N; Naing A; Ohanian M; Pant S; Pemmaraju N; Bose P; Piha-Paul SA; Rodon J; Salguero C; Sasaki K; Singh AK; Subbiah V; Tsimberidou AM; Xu QA; Yilmaz M; Zhang Q; Li Y; Bristow CA; Bhattacharjee MB; Tiziani S; Heffernan TP; Vellano CP; Jones P; Heijnen CJ; Kavelaars A; Marszalek JR; Konopleva M
Nat Med; 2023 Jan; 29(1):115-126. PubMed ID: 36658425
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism.
Farge T; Saland E; de Toni F; Aroua N; Hosseini M; Perry R; Bosc C; Sugita M; Stuani L; Fraisse M; Scotland S; Larrue C; Boutzen H; Féliu V; Nicolau-Travers ML; Cassant-Sourdy S; Broin N; David M; Serhan N; Sarry A; Tavitian S; Kaoma T; Vallar L; Iacovoni J; Linares LK; Montersino C; Castellano R; Griessinger E; Collette Y; Duchamp O; Barreira Y; Hirsch P; Palama T; Gales L; Delhommeau F; Garmy-Susini BH; Portais JC; Vergez F; Selak M; Danet-Desnoyers G; Carroll M; Récher C; Sarry JE
Cancer Discov; 2017 Jul; 7(7):716-735. PubMed ID: 28416471
[TBL] [Abstract][Full Text] [Related]
5. Cotargeting of Mitochondrial Complex I and Bcl-2 Shows Antileukemic Activity against Acute Myeloid Leukemia Cells Reliant on Oxidative Phosphorylation.
Liu F; Kalpage HA; Wang D; Edwards H; Hüttemann M; Ma J; Su Y; Carter J; Li X; Polin L; Kushner J; Dzinic SH; White K; Wang G; Taub JW; Ge Y
Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32847115
[TBL] [Abstract][Full Text] [Related]
6. Mechanism-Specific Pharmacodynamics of a Novel Complex-I Inhibitor Quantified by Imaging Reversal of Consumptive Hypoxia with [
Gammon ST; Pisaneschi F; Bandi ML; Smith MG; Sun Y; Rao Y; Muller F; Wong F; De Groot J; Ackroyd J; Mawlawi O; Davies MA; Gopal YNV; Di Francesco ME; Marszalek JR; Dewhirst M; Piwnica-Worms D
Cells; 2019 Nov; 8(12):. PubMed ID: 31766580
[TBL] [Abstract][Full Text] [Related]
7. Acute myeloid leukemia sensitivity to metabolic inhibitors: glycolysis showed to be a better therapeutic target.
Lapa B; Gonçalves AC; Jorge J; Alves R; Pires AS; Abrantes AM; Coucelo M; Abrunhosa A; Botelho MF; Nascimento-Costa JM; Sarmento-Ribeiro AB
Med Oncol; 2020 Jul; 37(8):72. PubMed ID: 32725458
[TBL] [Abstract][Full Text] [Related]
8. Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine.
Buettner R; Nguyen LXT; Morales C; Chen MH; Wu X; Chen LS; Hoang DH; Hernandez Vargas S; Pullarkat V; Gandhi V; Marcucci G; Rosen ST
J Hematol Oncol; 2021 Apr; 14(1):70. PubMed ID: 33902674
[TBL] [Abstract][Full Text] [Related]
9. Cancer metabolism, stemness and tumor recurrence: MCT1 and MCT4 are functional biomarkers of metabolic symbiosis in head and neck cancer.
Curry JM; Tuluc M; Whitaker-Menezes D; Ames JA; Anantharaman A; Butera A; Leiby B; Cognetti DM; Sotgia F; Lisanti MP; Martinez-Outschoorn UE
Cell Cycle; 2013 May; 12(9):1371-84. PubMed ID: 23574725
[TBL] [Abstract][Full Text] [Related]
10. SIRT3 deacetylase activity confers chemoresistance in AML via regulation of mitochondrial oxidative phosphorylation.
Ma J; Liu B; Yu D; Zuo Y; Cai R; Yang J; Cheng J
Br J Haematol; 2019 Oct; 187(1):49-64. PubMed ID: 31236919
[TBL] [Abstract][Full Text] [Related]
11. Targeting mitochondrial RNA polymerase in acute myeloid leukemia.
Bralha FN; Liyanage SU; Hurren R; Wang X; Son MH; Fung TA; Chingcuanco FB; Tung AY; Andreazza AC; Psarianos P; Schimmer AD; Salmena L; Laposa RR
Oncotarget; 2015 Nov; 6(35):37216-28. PubMed ID: 26484416
[TBL] [Abstract][Full Text] [Related]
12. Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ: visualizing the therapeutic effects of metformin in tumor tissue.
Whitaker-Menezes D; Martinez-Outschoorn UE; Flomenberg N; Birbe RC; Witkiewicz AK; Howell A; Pavlides S; Tsirigos A; Ertel A; Pestell RG; Broda P; Minetti C; Lisanti MP; Sotgia F
Cell Cycle; 2011 Dec; 10(23):4047-64. PubMed ID: 22134189
[TBL] [Abstract][Full Text] [Related]
13. SYK inhibition targets acute myeloid leukemia stem cells by blocking their oxidative metabolism.
Polak A; Bialopiotrowicz E; Krzymieniewska B; Wozniak J; Stojak M; Cybulska M; Kaniuga E; Mikula M; Jablonska E; Gorniak P; Noyszewska-Kania M; Szydlowski M; Piechna K; Piwocka K; Bugajski L; Lech-Maranda E; Barankiewicz J; Kolkowska-Lesniak A; Patkowska E; Glodkowska-Mrowka E; Baran N; Juszczynski P
Cell Death Dis; 2020 Nov; 11(11):956. PubMed ID: 33159047
[TBL] [Abstract][Full Text] [Related]
14. Disruption of mitochondrial oxidative phosphorylation by chidamide eradicates leukemic cells in AML.
Wang JD; Xu JQ; Long ZJ; Weng JY
Clin Transl Oncol; 2023 Jun; 25(6):1805-1820. PubMed ID: 36899123
[TBL] [Abstract][Full Text] [Related]
15. Inhibiting neddylation modification alters mitochondrial morphology and reprograms energy metabolism in cancer cells.
Zhou Q; Li H; Li Y; Tan M; Fan S; Cao C; Meng F; Zhu L; Zhao L; Guan MX; Jin H; Sun Y
JCI Insight; 2019 Feb; 4(4):. PubMed ID: 30668548
[TBL] [Abstract][Full Text] [Related]
16. Metabolic Enzyme DLST Promotes Tumor Aggression and Reveals a Vulnerability to OXPHOS Inhibition in High-Risk Neuroblastoma.
Anderson NM; Qin X; Finan JM; Lam A; Athoe J; Missiaen R; Skuli N; Kennedy A; Saini AS; Tao T; Zhu S; Nissim I; Look AT; Qing G; Simon MC; Feng H
Cancer Res; 2021 Sep; 81(17):4417-4430. PubMed ID: 34233924
[TBL] [Abstract][Full Text] [Related]
17. Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast Cancer.
Evans KW; Yuca E; Scott SS; Zhao M; Paez Arango N; Cruz Pico CX; Saridogan T; Shariati M; Class CA; Bristow CA; Vellano CP; Zheng X; Gonzalez-Angulo AM; Su X; Tapia C; Chen K; Akcakanat A; Lim B; Tripathy D; Yap TA; Francesco MED; Draetta GF; Jones P; Heffernan TP; Marszalek JR; Meric-Bernstam F
Cancer Res; 2021 Nov; 81(21):5572-5581. PubMed ID: 34518211
[TBL] [Abstract][Full Text] [Related]
18. Exogenous mitochondrial transfer and endogenous mitochondrial fission facilitate AML resistance to OxPhos inhibition.
Saito K; Zhang Q; Yang H; Yamatani K; Ai T; Ruvolo V; Baran N; Cai T; Ma H; Jacamo R; Kuruvilla V; Imoto J; Kinjo S; Ikeo K; Moriya K; Suzuki K; Miida T; Kim YM; Vellano CP; Andreeff M; Marszalek JR; Tabe Y; Konopleva M
Blood Adv; 2021 Oct; 5(20):4233-4255. PubMed ID: 34507353
[TBL] [Abstract][Full Text] [Related]
19. Biological and metabolic effects of IACS-010759, an OxPhos inhibitor, on chronic lymphocytic leukemia cells.
Vangapandu HV; Alston B; Morse J; Ayres ML; Wierda WG; Keating MJ; Marszalek JR; Gandhi V
Oncotarget; 2018 May; 9(38):24980-24991. PubMed ID: 29861847
[TBL] [Abstract][Full Text] [Related]
20. The thymidine dideoxynucleoside analog, alovudine, inhibits the mitochondrial DNA polymerase γ, impairs oxidative phosphorylation and promotes monocytic differentiation in acute myeloid leukemia.
Yehudai D; Liyanage SU; Hurren R; Rizoska B; Albertella M; Gronda M; Jeyaraju DV; Wang X; Barghout SH; MacLean N; Siriwardena TP; Jitkova Y; Targett-Adams P; Schimmer AD
Haematologica; 2019 May; 104(5):963-972. PubMed ID: 30573504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
